- Corporate
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX:BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.
News
Basel, Switzerland, April 29, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that new data on drug candidates from its development pipeline were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held in Berlin, Germany, from April 27 to 30.
more...
Basel, Switzerland, April 9, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that shareholders approved all agenda items proposed at today's Ordinary General Meeting of Shareholders for the financial year 2012. At the meeting, 59.9 percent of Basilea's share capital was represented.
more...
Basel, Switzerland, March 7, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN) released today the agenda for its April 9, 2013 Annual General Meeting (AGM).
more...
Basel, Switzerland, February 22, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN) has received a request from one of its shareholders, HBM Healthcare Investments (Cayman) Ltd., which holds more than 20% of Basilea's shares, to place the repayment of CHF 5.00 per registered share from the company's capital contribution reserve on the agenda of Basilea's upcoming ordinary general meeting of shareholders, for a total of approximately CHF 48 million.
more...
© 2013 Basilea Pharmaceutica Ltd.
